Biocon announced today in a letter to the National Stock Exchange of India that the FDA has extended its target action date for a regulatory decision on the drug maker’s trastuzumab biosimilar.
Biocon announced today in a letter to the National Stock Exchange of India that the FDA has extended its target action date for a regulatory decision on the drug maker’s trastuzumab biosimilar.
A company spokesperson said that the FDA “has notified our partner Mylan that they will extend the target action date for their [trastuzumab] 351(k) application to December 3, 2017 in order to review some of the clarificatory information submitted to them as part of the application review process. This [3-]month extension has no impact on the anticipated timetable for commercialization of this product in the [United States].”
A regulatory decision on the Indian drug maker’s biosimilar, MYL-1401O (referenced on Genentech’s Herceptin), had been expected on or before its Biosimilar User Fee Act date of September 3, 2017. The drug received a unanimous recommendation of approval from the FDA’s Oncologic Drugs Advisory Committee (ODAC) in July.
However, the drug has faced regulatory challenges in the European Union; earlier this month, Biocon withdrew its filings for both its trastuzumab product and its pegfilgrastim candidate from the European Medicines Agency (EMA). Biocon indicated that it would resubmit its applications to the EMA after regulators complete a re-inspection of its manufacturing facility in Bangalore. The re-inspection is required after France’s health regulatory body, the French National Agency for Medicines and Health Products Safety (ANSM), found that Biocon had failed to comply with good manufacturing practices in the production of 3 biosimilar products (including trastuzumab). ANSM identified 35 problems related to drug product manufacturing and quality control operations, and called 11 of those problems “major deficiencies.”
It is unclear whether the FDA’s delay of a decision on Biocon’s trastuzumab is related to the deficiencies in good manufacturing practices identified by ANSM or to the re-inspection of the facility. However, the FDA and the EMA recently signed a new confidentiality agreement allowing the agencies to share full inspection reports, including nonpublic, commercially confidential information related to inspections.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.